Page 6 - University Of Southampton Professors Sir Stephen Holgate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from University of southampton professors sir stephen holgate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In University Of Southampton Professors Sir Stephen Holgate Today - Breaking & Trending Today

Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial

1
: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces results from the Home Cohort of its SG016 Phase II trial of SNG001 in SARS-CoV-2 infected patients and data from the combined analysis of the Hospital and Home Cohorts.
SNG001 is a formulation containing IFN-beta for nebulisation, allowing it to be delivered directly into patients’ lungs. A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral responses by infected cells. Furthermore, some people have deficiencies in antiviral IFN signalling that make them more vulnerable to spread of the virus from the nose into the lungs where it can cause severe breathing difficulties. These findings provide a rationale to deliver IFN-beta directly to the surface epithelial cells of the lungs, the primary site of virus infection in the lun ....

United Kingdom , Olivia Manser , Geoff Nash , Mary Conway , Nick Francis , Richard Marsden , John Ward , Tom Wilkinson , Donna Davies , Duncan Monteith , Jessica Hodgson , James Black , Kate Bannatyne , Ratko Djukanovic , Mary Jane Elliott , Freddie Barnfield , Numis Securities Limited Joint Broker , University Of Southampton , United Kingdom National Institute For Health Research , Drug Administration , Consilium Strategic Communications Financial Media , National Institute For Health Research , University Of Southampton Professors Sir Stephen Holgate , Urgent Public Health , Foundation Trust Southampton , University Hospital Southampton ,

Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients

Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
( Synairgen or the Company )
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
Southampton, UK - 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation.
Richard Marsden, CEO of Synairgen, said: ....

United Kingdom , Olivia Manser , Geoff Nash , Richard Marsden , John Ward , Donna Davies , James Thompson , Duncan Monteith , James Black , Mary Jane Elliott , Ratko Djukanovic , Freddie Barnfield , Numis Securities Limited Joint Broker , University Of Southampton Professors Sir Stephen Holgate , National Institute Of Allergy , National Institutes Of Health , Clinical Trials Group , Consilium Strategic Communications Financial Media , National Institute , Infectious Diseases , National Institutes , Trials Group , Market Abuse Regulation , Chief Executive , Nominated Advisor , Joint Broker ,

Investegate |Synairgen plc Announcements | Synairgen plc: Inclusion in US ACTIV-2 trial

About Synairgen
Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection.
Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
COVID-19
COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease ....

United Kingdom , Olivia Manser , Geoff Nash , Richard Marsden , John Ward , Donna Davies , James Thompson , Duncan Monteith , James Black , Mary Jane Elliott , Ratko Djukanovic , Freddie Barnfield , Numis Securities Limited Joint Broker , Us National Institute Of Allergy , Human Services , Clinical Trials Group , Consilium Strategic Communications Financial Media , University Of Southampton Professors Sir Stephen Holgate , Us Department Of Health , Us National Institutes Of Health , Us Government Department Of Health , Infectious Diseases , Trials Group , Investigational New Drug , Operation Warp Speed , Market Abuse Regulation ,

UK's Synairgen Begins Major Trial for New Inhaler Based Treatment for Covid 19

A new potentially life-saving inhaler-based treatment which is expected will defend COVID-19 patients from developing severe illness has commenced a major trial at hospitals in the United Kingdom. It involves inhaling a protein called interferon beta-1a (SNG001), which the body produces when it gets a viral infection, and the expectation is it will kindle the body’s immune system and prime cells to be ready to fight off viruses.
Notably, Synairgen’s SG018 trial is a randomized placebo-controlled study being conducted in approximately 20 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen. “We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2 [COVID-19]. Development of treatments like ours will remain necessary in cases where vaccines are not effective, for those who do not get vaccinated, and in case the virus mutates to the point where vaccines become less effective,” said Richard Marsden, CEO ....

United Kingdom , Donna Davies , Ratko Djukanovic , Richard Marsden , University Of Southampton Professors Sir Stephen Holgate , Southampton Professors Sir Stephen Holgate , Uks Synairgen , Major Trial For New Inhaler Treatment , News Track Live , ஒன்றுபட்டது கிஂக்டம் , டோனா டேவிஸ் , ரிச்சர்ட் மார்ஸ்டன் , பல்கலைக்கழகம் ஆஃப் சவுத்தாம்ப்டன் ப்ரொஃபெஸ்ஸர்ஸ் ஐயா ஸ்டீபன் ஹோல்கேட் , சவுத்தாம்ப்டன் ப்ரொஃபெஸ்ஸர்ஸ் ஐயா ஸ்டீபன் ஹோல்கேட் , முக்கிய சோதனை க்கு புதியது இன்ஹேலர் சிகிச்சை , செய்தி டிராக் வாழ ,